Important current information of consensus statement of EAS on low-density lipoproteins: editorial
Authors:
Rudolf Poledne
Published in:
AtheroRev 2021; 6(1): 6
Category:
Sources
- Borén J, Chapman MJ, Krauss RM et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2020; 41(24): 2313–2330. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz962>.
- Kraml P, Vrablík M, Blaha V et al. Druhý konsenzus EAS o lipoproteinech o nízké hustotě: stanovisko výboru České společnosti pro aterosklerózu. AtheroRev 2021; 6(1): 9–16.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsArticle was published in
Athero Review
2021 Issue 1
Most read in this issue
- Inclisiran: the first siRNA approved by European Medicines Agency for treatment of dyslipidemias
- Second consensus statement of European Atherosclerosis Society on low-density lipoproteins: statement of Czech Society for Atherosclerosis
- Low concentration of plasma cholesterol and type 2. diabetes mellitus
- Early cardiovascular risk intervention means cummulation of positive impacts in time